ATE452871T1 - Amorphe hmg-coa-reduktase-inhibitoren mit gewünschter teilchengrösse - Google Patents

Amorphe hmg-coa-reduktase-inhibitoren mit gewünschter teilchengrösse

Info

Publication number
ATE452871T1
ATE452871T1 AT02717024T AT02717024T ATE452871T1 AT E452871 T1 ATE452871 T1 AT E452871T1 AT 02717024 T AT02717024 T AT 02717024T AT 02717024 T AT02717024 T AT 02717024T AT E452871 T1 ATE452871 T1 AT E452871T1
Authority
AT
Austria
Prior art keywords
coa reductase
particle size
desired particle
reductase inhibitors
hmg
Prior art date
Application number
AT02717024T
Other languages
English (en)
Inventor
Acharya Poornaprajna
Joy Mathew
Ravindra Chandrappa
Madhavan Sridharan
Sambasivam Ganesh
Original Assignee
Biocon Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocon Ltd filed Critical Biocon Ltd
Application granted granted Critical
Publication of ATE452871T1 publication Critical patent/ATE452871T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/48—Separation; Purification; Stabilisation; Use of additives
    • C07C67/52—Separation; Purification; Stabilisation; Use of additives by change in the physical state, e.g. crystallisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
AT02717024T 2002-03-18 2002-03-18 Amorphe hmg-coa-reduktase-inhibitoren mit gewünschter teilchengrösse ATE452871T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IN2002/000045 WO2003078379A1 (en) 2002-03-18 2002-03-18 AMORPHOUS Hmg-CoA REDUCTASE INHIBITORS OF DESIRED PARTICLE SIZE

Publications (1)

Publication Number Publication Date
ATE452871T1 true ATE452871T1 (de) 2010-01-15

Family

ID=27840281

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02717024T ATE452871T1 (de) 2002-03-18 2002-03-18 Amorphe hmg-coa-reduktase-inhibitoren mit gewünschter teilchengrösse

Country Status (16)

Country Link
US (1) US7230120B2 (de)
EP (1) EP1485343B1 (de)
JP (1) JP4308021B2 (de)
KR (1) KR100828653B1 (de)
AT (1) ATE452871T1 (de)
AU (1) AU2002247944B2 (de)
BR (1) BR0215644A (de)
CA (1) CA2479005C (de)
CZ (1) CZ2004943A3 (de)
DE (1) DE60234868D1 (de)
ES (1) ES2338530T3 (de)
HR (1) HRP20040967A2 (de)
HU (1) HUP0500074A3 (de)
IL (1) IL164020A0 (de)
NZ (1) NZ535910A (de)
WO (1) WO2003078379A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7655692B2 (en) 2003-06-12 2010-02-02 Pfizer Inc. Process for forming amorphous atorvastatin
CA2560252C (en) 2004-03-17 2009-08-04 Ranbaxy Laboratories Limited Process for the production of atorvastatin calcium in amorphous form
WO2006038219A1 (en) * 2004-10-05 2006-04-13 Biocon Limited Process for the preparation of amorphous fluvastatin sodium
KR20090033405A (ko) * 2004-10-18 2009-04-02 테바 파마슈티컬 인더스트리즈 리미티드 알콜 및 케톤 및/또는 에스테르의 혼합물인 유기 용매에 아토르바스타틴 헤미-칼슘 염을 용해시키고 용매를 제거하여 비결정형 아토르바스타틴 헤미-칼슘을 제조하는 방법
MX2007004722A (es) * 2004-10-28 2007-06-15 Warner Lambert Co Procedimiento para formar atorvastatina amorfa.
CA2547216A1 (en) 2005-09-21 2007-03-21 Renuka D. Reddy Process for annealing amorphous atorvastatin
US20070202159A1 (en) * 2006-02-02 2007-08-30 Mathur Rajeev S Pharmaceutical composition comprising stabilized statin particles
US8219173B2 (en) 2008-09-30 2012-07-10 Abbott Diabetes Care Inc. Optimizing analyte sensor calibration
US7834195B2 (en) 2007-01-24 2010-11-16 Apotex Pharmachem Inc. Atorvastatin calcium propylene glycol solvates
US20100204195A1 (en) * 2007-07-27 2010-08-12 Cipla Limited Pharmaceutical Compositions and Process for Making Them
WO2010066846A2 (en) * 2008-12-11 2010-06-17 Dsm Ip Assets B.V. Method for the isolation of atorvastatin

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK149080C (da) * 1980-06-06 1986-07-28 Sankyo Co Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre
FI94339C (fi) * 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
HRP960313B1 (en) * 1995-07-17 2002-08-31 Warner Lambert Co Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1)
HRP960312B1 (en) * 1995-07-17 2001-10-31 Warner Lambert Co NOVEL PROCESS FOR THE PRODUCTION OF AMORPHOUS /R-(R*, R*)/-2-(4-FLUOROPHENYL)-"beta", "delta"-DIHYDROXY-5-PHENYL-4-/(PHENYLAMINO)CARBONYL/-1H-PYRROLE -1-HEPTANOIC ACID CALCIUM SALT (2 : 1)
SI20305A (sl) 1999-08-06 2001-02-28 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Kristali natrijeve soli pravastatina
JP2002539108A (ja) 1999-03-08 2002-11-19 メルク エンド カムパニー インコーポレーテッド 結晶質水和ジヒドロキシオープンアシッドシンバスタチンカルシウム塩
US6646133B1 (en) * 2000-10-17 2003-11-11 Egis Gyogyszergyar Rt. Process for the preparation of amorphous atorvastatin calcium
HU226640B1 (en) * 1999-10-18 2009-05-28 Egis Gyogyszergyar Nyilvanosan Process for producing amorphous atorvastatin calcium salt
SI20425A (sl) 1999-12-10 2001-06-30 LEK tovarna farmacevtskih in kemi�nih izdelkov d.d. Priprava amorfnega atorvastatina
CA2421018A1 (en) * 2000-09-06 2002-03-14 Merck & Co., Inc. Dihydroxy open-acid salt of simvastatin
JP4234429B2 (ja) * 2000-11-16 2009-03-04 テバ ファーマシューティカル インダストリーズ リミティド 水酸化カルシウムによる〔Ｒ（Ｒ＊，Ｒ＊）〕−２−（４−フルオロフェニル）−β，δ−ジヒドロキシ−５−（１−メチルエチル）−３−フェニル−４−〔（フェニルアミノ）カルボニル〕−１Ｈ−ピロール−１−ヘプタン酸エステルの加水分解
US6777552B2 (en) 2001-08-16 2004-08-17 Teva Pharmaceutical Industries, Ltd. Processes for preparing calcium salt forms of statins
WO2003004450A1 (en) 2001-07-06 2003-01-16 Ciba Specialty Chemicals Holding Inc. Process for the preparation of intermediates useful in the synthesis of statin derivatives especially 7-amino 3,5-dihydroxy heptanoic acid derivatives, and intermediates thereof
HUP0401006A2 (hu) 2001-07-06 2004-08-30 Teva Pharmaceutical Industries Ltd. Eljárás 7-amino-szin-3,5-dihidroxi-heptánsav-származékok előállítására, ezek köztitermékei és módszerek az előállításukra
HRP20040116A2 (en) 2001-07-06 2004-10-31 Teva Pharma Process for the preparation of 7-amino syn 3,5-dihydroxy heptanoic acid derivatives via 6-cyano syn 3,5-dihydroxy hexanoic acid derivatives
EP1425287A4 (de) 2001-08-16 2005-09-07 Teva Pharma Verfahren zur herstellung von calciumsalzformen von statinen
WO2003068191A1 (en) 2002-02-14 2003-08-21 Ranbaxy Laboratories Limited Formulations of atorvastatin stabilized with alkali metal additions

Also Published As

Publication number Publication date
EP1485343A4 (de) 2006-05-31
HRP20040967A2 (en) 2005-06-30
IL164020A0 (en) 2005-12-18
JP2005520830A (ja) 2005-07-14
US7230120B2 (en) 2007-06-12
AU2002247944A1 (en) 2003-09-29
NZ535910A (en) 2006-04-28
CA2479005C (en) 2012-05-22
DE60234868D1 (de) 2010-02-04
CA2479005A1 (en) 2003-09-25
EP1485343B1 (de) 2009-12-23
EP1485343A1 (de) 2004-12-15
KR20040101279A (ko) 2004-12-02
CZ2004943A3 (cs) 2005-02-16
ES2338530T3 (es) 2010-05-10
HUP0500074A2 (hu) 2005-05-30
WO2003078379A1 (en) 2003-09-25
HUP0500074A3 (en) 2005-07-28
AU2002247944B2 (en) 2009-05-21
US20040186162A1 (en) 2004-09-23
KR100828653B1 (ko) 2008-05-09
JP4308021B2 (ja) 2009-08-05
BR0215644A (pt) 2004-12-21

Similar Documents

Publication Publication Date Title
HUS2100022I1 (hu) HIV integráz inhibitor hatású policiklusos karbamoil-piridon származékok
BRPI0413468A (pt) inibidores de hmg-coa redutase baseados em pirrol
TW200510002A (en) Solid pharmaceutical preparation
EA200801341A1 (ru) КОНДЕНСИРОВАННЫЕ БИЦИКЛИЧЕСКИЕ ИНГИБИТОРЫ mTOR
ATE452871T1 (de) Amorphe hmg-coa-reduktase-inhibitoren mit gewünschter teilchengrösse
DK1578733T3 (da) Fremgangsmåde til fremstilling af rosuvastatin
AU2003211576A1 (en) Histone deacetylase inhibitors and process for producing the same
AU2003260345A1 (en) 2-phenylpyridin-4-yl derivatives as alk5 inhibitors
AR045203A1 (es) Formas de dosificacion de inhibidores de la proteina de transferencia de colesteril ester e inhibidores de la hmg-coa reductosa
WO2005066151A3 (en) Histone deacetylase inhibitors
NO20052779D0 (no) Doseringsformer omfattende en CETP-inhibitor og en HMG-CoA-reduktaseinhibitor.
CY1113314T1 (el) (3-αρυλ-πιπεραζιν-1-υλ) παραγωγα της 6,7-διαλκοξυκιναζολινης, 6,7-διαλκοξυφθαλαζινης και 6,7-διαλκοξυϊσοκινολινης
FI20085346L (fi) Laite ja menetelmä liikuteltavan laitteen sijainnin jäljittämiseksi
EP1684754A4 (de) Hmg-coa-reduktase-hemmer und verfahren
TW200638950A (en) Dosage forms of cholesteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
CY1114742T1 (el) Συνδυασμος του αναστολεα αναγωγασης ημg-coa ροζουβαστατινης με αναστολεα φωσφοδιεστερασης 4, οπως η ροφλουμιλαστη, ν-οξειδιο ροφλουμιλαστης για τη θεραπεια φλεγμονωδων πνευμονικων νοσων
WO2005107873A3 (en) Glycopyrrolate for treating childhood asthma
TW200509993A (en) Process for forming amorphous atorvastatin
AU2003250172A1 (en) Compositions comprising hmg-coa reductase inhibitor
TW200720275A (en) Quinacridine derivatives and organic electronic devices using the same
DK1720949T3 (da) Fremgangsmåde til forbedring af lagerstabiliteten for kompositpartikeldispersioner
NO20053351D0 (no) Sporingsenhet for tyverisikring av objekter.
WO2007075870A3 (en) Processes for taxane derivatives and intermediates useful therein
TW200724688A (en) Process for producing atorvastatin, pharmaceutically acceptable salts thereof and intermediates thereof
BRPI0417138A (pt) n-alquil-pirroles como inibidores de hmg-coa-redutase

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties